Loading…
Simple
Expanded
Grid
By Venue
General Session [clear filter]
Tuesday, March 10
 

9:00am PDT

Chairperson’s Opening Remarks
Tuesday March 10, 2020 9:00am - 9:15am PDT
Presidio Ballroom
  General Session

9:15am PDT

Establish an Integrated and Optimized BD&L Process
  • Identify strategies to get the most out of your team during the entire BD&L process
  • Outline how to systemize the search and evaluation, diligence, contracting process
  • Discuss when specific team members get involved while the roles of others taper down
  • Define the roles, responsibilities, and efforts of each function at various parts of the life cycle
Speakers
avatar for John Krayacich

John Krayacich

Senior Vice President and Head, Global Business Development, LEO PHARMA
John Krayacich is the Senior Vice President & Head of Global Business Development at LEO Pharma. John joined LEO Pharma from Novartis Pharmaceuticals Corporation where he was Vice President, Strategic Planning and Business Development & Licensing. Prior to joining Novartis, John spent... Read More →

Tuesday March 10, 2020 9:15am - 10:00am PDT
Presidio Ballroom
  General Session

10:00am PDT

Compare and Contrast Different Operating Models for Search and Evaluation to Advance Innovation
  • Analyze new growth opportunities and how they should align favorably with your company’s growth culture and objectives
  • Discuss the various formal processes, metrics, and models for prioritization
  • Understand the broader goals of your business development strategy, such as geographic expansion, market share increases, and accelerated top-line growth
  • Weigh the pros and cons of R&D and innovation hubs as a way to partner with existing ecosystems
Speakers
avatar for Angele Maki, Ph.D.

Angele Maki, Ph.D.

Vice President, Emerging Technology and Innovation, ELI LILLY AND COMPANY
avatar for Jennifer Leeds, Ph.D.

Jennifer Leeds, Ph.D.

Executive Director, BD&L, NOVARTIS
avatar for Ravi Kiron, Ph.D., MBA

Ravi Kiron, Ph.D., MBA

Head, BioPharma External Innovation, EMD SERONO/MERCK KGAA, DARMSTADT, GERMANY
Dr. Ravi Kiron based in California, USA is an experienced pharma/biotech executive with decades of experience in discovery R&D through late-stage clinical development, intellectual property and regulatory, technology & business development, M&A, strategy and product commercialization... Read More →
avatar for Lisa Mendoza, Ph.D.

Lisa Mendoza, Ph.D.

Director External Research and Alliances, BAYER
Dr. Lisa Mendoza is Director with Bayer’s R&D partnering organization located in San Francisco at Bayer’s Open Innovation Center.  Dr. Mendoza has established partnerships with academic and biotech researchers focused on novel therapeutics of strategic interest to Bayer with... Read More →

Tuesday March 10, 2020 10:00am - 10:45am PDT
Presidio Ballroom
  General Session

11:15am PDT

Negotiating a Term Sheet: Strategic and Tactical Considerations
  • Why do a term sheet? Explore the purpose of the term sheet – avoid surprises or gentleperson’s handshake?
  • Fit for purpose approach versus kitchen sink - what should be negotiated at the term sheet level versus in the definitive agreement?
  • Small company versus large company perspectives and priorities
Speakers
avatar for Mark Kafka

Mark Kafka

Assistant General Counsel, GENENTECH
avatar for Jeannie Karl

Jeannie Karl

Senior Corporate Counsel, GENENTECH
avatar for Stephanie Yonker, Ph.D., J.D.

Stephanie Yonker, Ph.D., J.D.

Vice President of Legal and Corporate Secretary, ALECTOR
avatar for Nick Galli, J.D.

Nick Galli, J.D.

Senior Vice President, Chief Business Officer, CYTOMX THERAPEUTICS

Tuesday March 10, 2020 11:15am - 12:00pm PDT
Presidio Ballroom
  General Session

12:00pm PDT

Navigate BD Deals Involving Digital Health Targets
  • Consider the various product categories that can fall under the “digital health” definition
  • Understand the impact technology can have on the effectiveness of your operations and product portfolio
  • Analyze different valuation approaches and how it can be difficult to monetize or attribute a value to the benefits of digital health assets
  • Consider key questions to ask during the diligence process
Speakers
avatar for Antoun Nabhan, J.D.

Antoun Nabhan, J.D.

Vice President, Corporate Development, PEAR THERAPEUTICS
Antoun has experience leading the corporate development and/or finance functions at several successful biotechnology and medical device companies.Antoun Nabhan was Vice President of Corporate Development at Raptor Pharmaceuticals, Inc., where he oversaw licensing and strategic transactions... Read More →

Tuesday March 10, 2020 12:00pm - 12:45pm PDT
Presidio Ballroom
  General Session
 
Wednesday, March 11
 

9:00am PDT

Recap of Day One
Wednesday March 11, 2020 9:00am - 9:15am PDT
Presidio Ballroom
  General Session

9:15am PDT

Lilly Chorus: A Model to Collaborate, Accelerate, and Innovate
  • Examine how Chorus, an autonomous R&D unit within Eli Lilly, functions as a lean approach to develop, de-risk and increase the value of early phase assets
  • Explore how this model aligns with Lilly’s capital fund strategy and works with outside venture capital to continue programs outside of Lilly’s core focus areas
  • Hear case examples and success stories since Chorus’ inception
Speakers
avatar for Angele Maki, Ph.D.

Angele Maki, Ph.D.

Vice President, Emerging Technology and Innovation, ELI LILLY AND COMPANY

Wednesday March 11, 2020 9:15am - 10:00am PDT
Presidio Ballroom
  General Session

10:00am PDT

Uncertainty, Challenges, and Implications of Today’s Reimbursement Environment on the Deal-Making Landscape
  • Consider the rising importance of a product’s commercial versus clinical success when evaluating a potential target
  • Discuss the impact of payer consolidation and the evolving healthcare landscape
  • Explore how pricing practices have drawn public and government scrutiny and how this close examination has impacted deal structuring
Speakers
avatar for Sheldon L Koenig, MBA

Sheldon L Koenig, MBA

Executive Vice President and Chief Commercial Officer, PORTOLA PHARMACEUTICALS

Wednesday March 11, 2020 10:00am - 10:45am PDT
Presidio Ballroom
  General Session

11:15am PDT

Explore Innovative Deal Constructs and Risk-Sharing Structures for Licensing and Acquisition Deals
  • Review the risks and hurdles to watch out for from an accounting point of view
  • Evaluate how robust your governance structure should be before you start to control the development of an options-based asset
  • Discuss the best ways to structure options agreements and how to minimize exposure to your P&L while ensuring the requisite controls needed
Speakers
avatar for Jay Parrish

Jay Parrish

Chief Business Officer, VIR BIOTECHNOLOGY
avatar for Neil Abdollahian, M.S., M.B.A.

Neil Abdollahian, M.S., M.B.A.

Chief Business Officer, CIDARA THERAPEUTICS
Neil Abdollahian, M.S. MBA, has 20 years of corporate strategy, partnering and M&A experience in the biopharmaceutical industry and currently leads Cidara’s corporate development strategy and execution.Mr. Abdollahian’s career has been focused on building companies through strategic... Read More →
avatar for Matt Panuwat

Matt Panuwat

Chief Business Officer, ORIC PHARMACEUTICALS
Prior to joining ORIC recently as Chief Business Officer, Matt was Senior Vice President of Business Development at Prothena, where he led partnership activities and established the company’s global research & development collaboration with Celgene. Prior to Prothena, he was Head... Read More →

Wednesday March 11, 2020 11:15am - 12:00pm PDT
C.A. Thayer
  General Session

1:00pm PDT

Key Considerations for M&A and Asset Purchases From a Private Company
  • Establish what the deductible will be and how the liability works
  • Gain an understanding of their compliance history and how things can go south in a deal
  • Outline best practices for protecting your organization as an acquirer of rights and ensuring last year’s taxes are clean
Speakers
avatar for Timothy Herpin, Ph.D.

Timothy Herpin, Ph.D.

Vice President, Janssen Business Development, Infectious Diseases and Vaccines
Tim Herpin is Vice-President, Janssen Business Development, Infectious Diseases and Vaccines. In this role, he leads the strategy and planning of all business development activities in support of Janssen’s Infectious Diseases and Vaccines therapeutic area. Before joining Johnson... Read More →
avatar for Irina Ridley

Irina Ridley

Chief Counsel, MYRIAD GENETICS

Wednesday March 11, 2020 1:00pm - 1:45pm PDT
Presidio Ballroom
  General Session

1:45pm PDT

Corporate Venture Funds — Strategic Partners or Not?
  • Assess the rationale and motivations for building a corporate venture arm
  • Learn how the corporate venture funds operate within the constructs of big pharma that are not typically designed for these sort of investments
  • Consider the benefits of working as a strategic partner with your BD colleagues
  • Discuss how you manage competition with external VCs as well as internal BD groups
Wednesday March 11, 2020 1:45pm - 2:30pm PDT
Presidio Ballroom
  General Session

2:30pm PDT

Conference Concludes
Wednesday March 11, 2020 2:30pm - 2:30pm PDT
Presidio Ballroom
  General Session
 
Filter sessions
Apply filters to sessions.
Tuesday, March 10
Wednesday, March 11
C.A. Thayer
North Point Lounge
Presidio Ballroom
  • Business Development
  • General Session
  • Legal/Transactions
  • Networking